Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type|Pathology location|Pathology Description|
17-4-1|n/a,n/a|1|500|X-rays whole body|1.8|grays|External exposure local|mean dose BM from unilateral, dogs age 12-20 months|6 (0 in ERA)|Dog|Dog, Beagle|Both|Young Adult|haematological parameters, bone marrow GM-CFC, CFU-F serum CSA sequential studies over one year|No information on individuals available for this study
17-4-2|n/a,n/a|1|500|X-rays whole body|1.7|grays|External exposure|mean dose BM from bilateral, dogs age 12 -20 months|3 (0 in ERA)|Dog|Dog, Beagle|Both|Young Adult|haematological parameters, bone marrow GM-CFC, CFU-F serum CSA sequential studies over one year|No information on individuals available for this study
